Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific Inc. (NYSE: TMO) is frequently in the news as the world leader in serving science, with disclosures and press releases covering its activities across life sciences, diagnostics, analytical instruments and pharma services. News about Thermo Fisher often highlights how the company’s technologies and services support customers in accelerating life sciences research, solving analytical challenges, improving laboratory productivity, enhancing diagnostics and enabling the development and manufacture of life‑changing therapies.
Recent Thermo Fisher news includes strategic collaborations, regional investments, product clearances, capital allocation decisions and financing transactions. The company announced a collaboration with NVIDIA to power AI‑based solutions and laboratory automation, pairing its scientific instruments and lab software with NVIDIA’s AI infrastructure to increase automation, accuracy and speed in laboratories. It also reported an expansion of its bioprocessing capabilities in Asia through Bioprocess Design Centers in Incheon, Hyderabad and Singapore, aimed at supporting the region’s biopharmaceutical industry.
Thermo Fisher’s news flow also covers regulatory and clinical milestones, such as 510(k) clearance in the United States for the EXENT System, an automated platform designed as an aid in the diagnosis of multiple myeloma and related disorders. Financial and corporate updates include announcements of euro‑denominated and U.S. dollar‑denominated senior note offerings, a $5 billion share repurchase authorization, quarterly dividends, and agreements and completions related to acquisitions such as Solventum Corporation’s purification and filtration business and Clario Holdings, Inc.
Visitors to this TMO news page can review a stream of these company‑specific developments, from earnings‑related announcements and conference presentations to leadership changes and strategic initiatives disclosed in press releases and SEC‑linked communications.
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a quarterly cash dividend of $0.35 per common share, a 17% increase from the previous $0.30 dividend. This payment will be made on April 14, 2023, to stockholders recorded by March 15, 2023. The company, a leader in scientific services with annual revenues exceeding $40 billion, focuses on contributing to societal health and safety through innovative technologies and comprehensive laboratory services.
NATICK, Mass. - Mercy BioAnalytics announced that Dawn Mattoon, PhD, has taken over as Chief Executive Officer, transitioning from her previous role as Chief Operating Officer. Paul Blavin has moved to the position of Vice Chairman of the Board. Dr. Mattoon, who has been with the company for seven months, praised the team's progress in advancing their cancer detection technology. Her experience includes leadership roles in strategic initiatives at companies like Quanterix and Thermo Fisher Scientific. The company focuses on the early detection of cancers, particularly ovarian and lung cancers, through its Mercy Halo liquid biopsy platform.
Thermo Fisher Scientific (NYSE: TMO) announced a major step towards achieving its net-zero carbon emissions goal by 2050. The company signed a 20-year virtual power purchasing agreement with EDF Renewables to supply 545,000 MWh of renewable electricity annually from a new 200 MW solar project in Texas. By 2026, Thermo Fisher aims to power all U.S. operations entirely with renewable electricity. This initiative supports an increased target to cut Scope 1 and 2 greenhouse gas emissions by 50% from 2018 levels by 2030. The Millers Branch Solar project is set to be operational by December 2025, marking a significant shift toward sustainable practices.
Thermo Fisher Scientific Inc. (TMO) reported its Q4 and full-year 2022 results, showing a 7% increase in quarterly revenue to $11.45 billion and a 15% increase in annual revenue to $44.92 billion. The fourth quarter GAAP EPS was $4.01, down from $4.17 in 2021, while adjusted EPS was $5.40, compared to $6.54 previously. Notable achievements included the launch of innovative products and expansions in global capabilities. The company initiated 2023 guidance, expecting $45.3 billion in revenue and $23.70 in adjusted EPS.
Thermo Fisher Scientific Inc. (NYSE: TMO) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 10:30 a.m. (EST). CEO Marc N. Casper will lead the presentation, showcasing the company's commitment to advancing science globally. Thermo Fisher, with an annual revenue of approximately $40 billion, aims to make the world healthier, cleaner, and safer.
Investors can access the presentation via the Investors section of their website.
Thermo Fisher Scientific Inc. (NYSE: TMO) is set to release its financial results for Q4 and full year 2022 on
Thermo Fisher Scientific has completed its acquisition of The Binding Site Group for £2.3 billion ($2.8 billion). This acquisition expands Thermo Fisher's Specialty Diagnostics segment, enhancing its capabilities in oncology testing for multiple myeloma. The Binding Site's offerings are crucial for early diagnosis and monitoring of blood cancers, significantly improving patient outcomes. The transaction is expected to boost adjusted earnings per share by $0.07 in 2023. Thermo Fisher continues to lead in serving science with a projected annual revenue of around $40 billion.
Thermo Fisher Scientific has announced the pricing of a €1.25 billion offering of euro-denominated senior notes. The offering includes €500 million of 3.200% senior notes due 2026 and €750 million of 3.650% senior notes due 2034. The expected closing date is on or about November 21, 2022. Proceeds from this offering will fund general corporate purposes, including acquisitions and debt refinancing. The company operates under an effective registration statement with the SEC, ensuring compliance and transparency for investors.
Thermo Fisher Scientific, trading under TMO, has announced the pricing of a $1.2 billion bond offering, which includes $600 million in senior notes due 2027 with a 4.800% interest rate and $600 million in senior notes due 2032 with a 4.950% interest rate. The offering is set to close by November 21, 2022, subject to standard conditions. Proceeds will support various corporate purposes, including debt repayment and acquisitions. The offering is managed by BofA Securities, Citigroup, and Deutsche Bank.
FAQ
What is the current stock price of Thermo Fishr Sci (TMO)?
What is the market cap of Thermo Fishr Sci (TMO)?
